Pulmonary HypertensionNCT04450862
Anxiety Self-management Intervention for Pulmonary Hypertension
A study testing Cognitive Behavioural therapy self help intervention for anxiety in people with Pulmonary Hypertension and Pulmonary Arterial Hypertension, run by University of Sheffield at 2 sites in United Kingdom.
Trial summary
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Anxiety
- What is being tested?
- Cognitive Behavioural therapy self help intervention for anxiety
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 5 Aug 2020to 30 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- • Aged 18 years or over
- Diagnosis of pulmonary hypertension - participants will be asked to self-report this information
- Able to complete the self-report questionnaires without help from others
- Able to give informed consent - given that participants need to be proactive in entering the study, this will be assumed.
- Literate in English
Who cannot join
- • Significant risk issues (participants will be asked to self-report this information), for example, experiencing current thoughts of self-harm or suicide.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites, 2 recruiting
- Recruiting
Clinical Psychology Unit
Sheffield, South Yorkshire, S1 2LT
Amrit Sinha, 0114 2226650, A.Sinha@sheffield.ac.uk
Nigel Beail, Prof
- Recruiting
Clinical Psychology Unit
Sheffield
Amrit Sinha
a.sinha@sheffield.ac.uk
About this study
Official title: Development and Pilot Randomised Controlled Trial of a Self-management Intervention to Help Individuals With Pulmonary Hypertension Live Better With Anxiety
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders. There is limited evidence on psychological treatments for anxiety in PH; however, results support the use of Cognitive Behavioural Therapy (CBT). Despite the prevalence and impact of anxiety in PH; there are no widely available and/or disease specific pathways, thus highlighting an unmet need in this population. This project aims to develop and pilot, using randomised control trial methodology, a self-management intervention for individuals with PH based on principles of CBT.
Read the detailed description
Project Objectives The primary aim of this study is to develop a self-management intervention in collaboration with patient, public involvement, which will consist of experts by experience and experts by education. The intervention is aimed at helping individuals with PH to manage symptoms of anxiety.
A secondary aim of the project is to conduct a pilot randomised controlled trial investigating the aforementioned self-management intervention. More specifically, the project will explore acceptability and feasibility of the intervention itself and research methodology proposed to test its effectiveness. Qualitative and quantitative data will be collected for this purpose which will focus on: attrition rates; adherence to the intervention; participant's acceptability of the intervention and research methodology (i.e. eligibility, randomisation, emotional response, perceptions); outcome measures; recruitment and data collection procedures; and any adverse effects. Moreover, this project will investigate the preliminary efficacy of the intervention on a series of primary (anxiety symptoms - Generalised Anxiety Disorder -7) and secondary measures (depression - PHQ9); HRQoL- emphasis10); dyspnoea - dyspnoea12; perception of coping - self-mastery questionnaire; and cognitive and behavioural processes (Cognitive Behavioural Processes Questionnaire (CBPQ), so that effect sizes can be calculated and used to inform sample sizes of any future definitive trials.
Design The study will be a pilot randomised superiority trial. Participants will be randomised on a 1:1 basis to either one of two groups, (1) CBT informed self-management intervention to help manage anxiety in PH or a (2) controlled waiting-list condition. A control condition is required to control for any therapeutic gains associated with being involved in a trial. Participants will be asked to complete a series of measures pre-, post- and one month following completion of the intervention. As such, a 2 (cognitive-behavioural informed intervention or control waiting list) x 3 (pre-, post- and intervention) research design will be used. Participants or researchers will not be blinded to condition allocation (i.e. participants will be aware they may be randomised to a waiting list condition, and researchers may be contacting participants during the intervention for feedback on adherence and acceptability).
Procedure From the study advert promoted by the Pulmonary Hypertension Association, participants will be directed to a dedicated webpage for the proposed project.
From there, participants will be able to read the participant information sheet. Participants interested in talking part will be asked to click on a link that will take them to a series of questionnaire hosted by Qualtrics. Participants will first be asked to complete an eligibility form. Based on their responses, if participants are not eligible they will be informed immediately that they are unable to participate in the study. If participants are eligible, they will be asked to complete a consent form and a series of questionnaires (see below). All data entered on this page will be recorded, as it will help to inform feasibility of the inclusion/exclusion criteria (i.e. is the study excluding a large percentage of people based on a certain factor).
Participants will also be informed on the advert promoted by the Pulmonary Hypertension Association, that they can contact the lead researcher (Gregg Rawlings) to ask any additional questions about the project prior to completing the eligibility form, consent form and/or questionnaires.
Eligible participants will be randomised, using an online randomiser, to either of the two arms. The programme used to randomise will be Random.org. Those randomised to the wait-list condition will be informed that they will be contacted again in four weeks asking them to complete a series of questionnaires and again in an additional month (see below). Those in the intervention condition will be sent the CBT intervention.
Participants in the intervention condition will be instructed to work systematically through the intervention. Two weeks after the intervention is sent to participants, participants will be contacted by the lead researcher (Gregg Rawlings) to check on adherence and acceptability of the intervention using a mixed-methods structured questionnaire. Participants will be attempted to be contacted a maximum of three times. Participants will have provided prior consent to be contacted.
Four weeks following the intervention being received and one month thereafter participants will be contacted asking them to complete the outcome measures (see below). During this time, participants will be contacted asking them to complete a quantitative and qualitative questionnaire on their views of participating in the intervention. This will be hosted by Qualitrics. Participants will have provided consent to be contacted for this purpose.
Data analysis
Quantitative data:
- Descriptive statistics, and a series of independent T-tests for continuous data and chi square tests for categorical data will be used to compare participants in the two intervention arms at baseline. This will help to indicate whether randomisation was effective and inform additional analyses i.e. certain variables may need to be controlled for using ANCOVAs or ANCOVA.
- A series of independent T-tests for continuous data and chi square tests for categorical data will be used to compare participants who have dropped out versus those who completed the study. This will help to further understand acceptability and reasons for attrition.
- Descriptive statistics will be reported for rates of attrition and data collected from the feedback questionnaires.
- To explore the potential effectiveness of the intervention, a mixed ANOVA or ANCOVA analysis will be conducted with assessment (pre-, post-intervention and one-month follow) being the within subjects factors and intervention arm (self-help intervention or waitlist) being the between subject factor. This will be conducted for the primary measure and each of the secondary measures. As this is a pilot study and not testing effectiveness specifically, intent to treat analysis and Bonferroni corrections will not be performed. Cohen's d will be used to interpret observed effect sizes using the parameters discussed above. A significance level of alpha (0.05) will be adopted for all statistical analysis reported. SPSS25 will be used for all statistical analysis.
- To calculate the post-hoc power analysis to inform sample sizes of future definitive randomised controlled trials, G*Power software will be used utilising the same parameters as above (i.e. two-tailed, alpha level and 80% power) - given the assumptions of the ANOVA or ANCOVA were met and therefore the effect size is valid. This will be conducted using the results from the primary outcome measure (GAD-7) and an average size of secondary measures.
Qualitative data: Qualitative data gathered from the feedback questionnaires will be analysed using a descriptive version of thematic analysis. This will adhere to the stages outline by Braun and Clarke:
- Become familiar with the transcripts through repeated readings - participant's responses will already be in electronic format as it is collected via Qualtrics and so transcriptions will not be needed.
- Undertake iterative coding of each transcript re-coding each narrative as new codes emerge.
- Collate and contrast codes to create main- and sub-themes.
- Review the themes and discuss the findings with members of the research team.
- Final refinement of themes identifying clear titles and selecting appropriate quotations in support of each theme.
- Write up the report making the outcome of the analysis coherent.
- Being tested
- Cognitive Behavioural therapy self help intervention for anxiety
- Medical subject headings
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Behavioural therapy self help intervention for anxietyOther
The intervention will involve five key components:
Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.
Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.
Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.
Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.
Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving.
| Study group | Role | What they receive |
|---|---|---|
| Intervention arm | Experimental | Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky \& Mooney, 1990). Receives: Other: Cognitive Behavioural therapy self help intervention for anxiety |
| Control arm | No intervention | A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Generalised Anxiety Disorder-7 (GAD-7)
The Generalised Anxiety Disorder-7 (GAD-7) is a seven-item scale, self-administered screening tool and anxiety severity measure for anxiety disorders including, generalised anxiety disorder, social anxiety and panic disorder. Scores range from 0-21. A score of 0-4 indicates "no difficulties", 5-9 "mild", 10-14 "moderate" and 15-21 "severe" levels. A higher score suggests greater anxiety.
Measured: pre intervention, post intervention (4 weeks after) and 1 month follow up
Secondary outcomes (5)
Change in Patient Health Questionnaire-9 (PHQ9)
The Patient Health Questionnaire-9 (PHQ9) is a nine-item, self-administered tool to examine severity of depression. Scores range from 0-27. A score of 0-4 indicates "no difficulties", 5-9 "mild", 10-14 "moderate", 15-19 "moderately severe" and 20 or higher "severe depression". A higher score suggests greater depression.
Measured: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in emPHasis-10
This is a disease-specific, health-related quality of life measure asking respondents to rate ten difficulties commonly associated with PH. Scores can range form 0-50, with a higher score indicating lower quality of life.
Measured: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in Dyspnoea 12 (D12)
The Dyspnoea 12 (D12) will be used to examine participant's breathlessness severity. Total scores range from 0-36 with a higher score indicating worse functioning
Measured: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in Mastery Scale
The Mastery Scale will be used to investigate participant's perception of their own ability of coping. Total scores range from 7-49 with a higher score suggesting the individual perceives himself or herself as having a greater capacity to cope
Measured: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in Cognitive Behavioural Processes Questionnaire (CBPQ)
The Cognitive Behavioural Processes Questionnaire (CBPQ) will be used to examine participant's responses to negative cognitions, emotions and behaviours that may themselves underlie anxiety disorders. Scores range from 0-120, with higher scores suggesting lower engagement in cognitive and behavioural processes.
Measured: pre intervention, post intervention (4 weeks after) and 1 month follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2020
- Study start5 Aug 2020
- Primary completionApr 2021 (estimated)
- Study completion30 Aug 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Pulmonary HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomised controlled trial
- Masking
- None (open label)
- Enrolment
- 64 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Sheffield
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gregg H Rawlings, PhD, Principal investigator, University of Sheffield
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04450862
- Sponsor's protocol ID
- 034442
- Status last verified
- Jun 2020
- First submitted
- 19 Jun 2020
- Last updated
- 10 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Participant's data will not be shared with researchers outside of the research team. Participants will be anonymised in all publications.
Publications
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
PubMed 16717171Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, Pollock V, Armstrong I. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014 Apr;43(4):1106-13. doi: 10.1183/09031936.00127113. Epub 2013 Nov 14.
PubMed 24232702Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010 Jan;65(1):21-6. doi: 10.1136/thx.2009.118521. Epub 2009 Dec 8.
PubMed 19996336
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Pilot Randomised Controlled Trial of a Self-management Intervention to Help Individuals With Pulmonary Hypertension Live Better With Anxiety
- ClinicalTrials.gov ID
- NCT04450862
- Acronym / sponsor ID
- 034442
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 64 participants (estimated)
- Lead sponsor
- University of SheffieldUniversity, hospital or other
- Study start
- 5 Aug 2020 (actual)
- Primary completion
- Apr 2021 (estimated)
- Study completion
- 30 Aug 2021 (estimated)
- First posted
- 30 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders. There is limited evidence on psychological treatments for anxiety in PH; however, results support the use of Cognitive Behavioural Therapy (CBT). Despite the prevalence and impact of anxiety in PH; there are no widely available and/or disease specific pathways, thus highlighting an unmet need in this population. This project aims to develop and pilot, using randomised control trial methodology, a self-management intervention for individuals with PH based on principles of CBT.
Detailed description
Project Objectives The primary aim of this study is to develop a self-management intervention in collaboration with patient, public involvement, which will consist of experts by experience and experts by education. The intervention is aimed at helping individuals with PH to manage symptoms of anxiety.
A secondary aim of the project is to conduct a pilot randomised controlled trial investigating the aforementioned self-management intervention. More specifically, the project will explore acceptability and feasibility of the intervention itself and research methodology proposed to test its effectiveness. Qualitative and quantitative data will be collected for this purpose which will focus on: attrition rates; adherence to the intervention; participant's acceptability of the intervention and research methodology (i.e. eligibility, randomisation, emotional response, perceptions); outcome measures; recruitment and data collection procedures; and any adverse effects. Moreover, this project will investigate the preliminary efficacy of the intervention on a series of primary (anxiety symptoms - Generalised Anxiety Disorder -7) and secondary measures (depression - PHQ9); HRQoL- emphasis10); dyspnoea - dyspnoea12; perception of coping - self-mastery questionnaire; and cognitive and behavioural processes (Cognitive Behavioural Processes Questionnaire (CBPQ), so that effect sizes can be calculated and used to inform sample sizes of any future definitive trials.
Design The study will be a pilot randomised superiority trial. Participants will be randomised on a 1:1 basis to either one of two groups, (1) CBT informed self-management intervention to help manage anxiety in PH or a (2) controlled waiting-list condition. A control condition is required to control for any therapeutic gains associated with being involved in a trial. Participants will be asked to complete a series of measures pre-, post- and one month following completion of the intervention. As such, a 2 (cognitive-behavioural informed intervention or control waiting list) x 3 (pre-, post- and intervention) research design will be used. Participants or researchers will not be blinded to condition allocation (i.e. participants will be aware they may be randomised to a waiting list condition, and researchers may be contacting participants during the intervention for feedback on adherence and acceptability).
Procedure From the study advert promoted by the Pulmonary Hypertension Association, participants will be directed to a dedicated webpage for the proposed project.
From there, participants will be able to read the participant information sheet. Participants interested in talking part will be asked to click on a link that will take them to a series of questionnaire hosted by Qualtrics. Participants will first be asked to complete an eligibility form. Based on their responses, if participants are not eligible they will be informed immediately that they are unable to participate in the study. If participants are eligible, they will be asked to complete a consent form and a series of questionnaires (see below). All data entered on this page will be recorded, as it will help to inform feasibility of the inclusion/exclusion criteria (i.e. is the study excluding a large percentage of people based on a certain factor).
Participants will also be informed on the advert promoted by the Pulmonary Hypertension Association, that they can contact the lead researcher (Gregg Rawlings) to ask any additional questions about the project prior to completing the eligibility form, consent form and/or questionnaires.
Eligible participants will be randomised, using an online randomiser, to either of the two arms. The programme used to randomise will be Random.org. Those randomised to the wait-list condition will be informed that they will be contacted again in four weeks asking them to complete a series of questionnaires and again in an additional month (see below). Those in the intervention condition will be sent the CBT intervention.
Participants in the intervention condition will be instructed to work systematically through the intervention. Two weeks after the intervention is sent to participants, participants will be contacted by the lead researcher (Gregg Rawlings) to check on adherence and acceptability of the intervention using a mixed-methods structured questionnaire. Participants will be attempted to be contacted a maximum of three times. Participants will have provided prior consent to be contacted.
Four weeks following the intervention being received and one month thereafter participants will be contacted asking them to complete the outcome measures (see below). During this time, participants will be contacted asking them to complete a quantitative and qualitative questionnaire on their views of participating in the intervention. This will be hosted by Qualitrics. Participants will have provided consent to be contacted for this purpose.
Data analysis
Quantitative data:
- Descriptive statistics, and a series of independent T-tests for continuous data and chi square tests for categorical data will be used to compare participants in the two intervention arms at baseline. This will help to indicate whether randomisation was effective and inform additional analyses i.e. certain variables may need to be controlled for using ANCOVAs or ANCOVA.
- A series of independent T-tests for continuous data and chi square tests for categorical data will be used to compare participants who have dropped out versus those who completed the study. This will help to further understand acceptability and reasons for attrition.
- Descriptive statistics will be reported for rates of attrition and data collected from the feedback questionnaires.
- To explore the potential effectiveness of the intervention, a mixed ANOVA or ANCOVA analysis will be conducted with assessment (pre-, post-intervention and one-month follow) being the within subjects factors and intervention arm (self-help intervention or waitlist) being the between subject factor. This will be conducted for the primary measure and each of the secondary measures. As this is a pilot study and not testing effectiveness specifically, intent to treat analysis and Bonferroni corrections will not be performed. Cohen's d will be used to interpret observed effect sizes using the parameters discussed above. A significance level of alpha (0.05) will be adopted for all statistical analysis reported. SPSS25 will be used for all statistical analysis.
- To calculate the post-hoc power analysis to inform sample sizes of future definitive randomised controlled trials, G*Power software will be used utilising the same parameters as above (i.e. two-tailed, alpha level and 80% power) - given the assumptions of the ANOVA or ANCOVA were met and therefore the effect size is valid. This will be conducted using the results from the primary outcome measure (GAD-7) and an average size of secondary measures.
Qualitative data: Qualitative data gathered from the feedback questionnaires will be analysed using a descriptive version of thematic analysis. This will adhere to the stages outline by Braun and Clarke:
- Become familiar with the transcripts through repeated readings - participant's responses will already be in electronic format as it is collected via Qualtrics and so transcriptions will not be needed.
- Undertake iterative coding of each transcript re-coding each narrative as new codes emerge.
- Collate and contrast codes to create main- and sub-themes.
- Review the themes and discuss the findings with members of the research team.
- Final refinement of themes identifying clear titles and selecting appropriate quotations in support of each theme.
- Write up the report making the outcome of the analysis coherent.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomised controlled trial
| Arm | Type | Receives |
|---|---|---|
| Intervention arm | Experimental | Other: Cognitive Behavioural therapy self help intervention for anxietyParticipants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky \& Mooney, 1990). |
| Control arm | No intervention | –A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- • Aged 18 years or over
Key exclusion criteria (1 listed)
- • Significant risk issues (participants will be asked to self-report this information), for example, experiencing current thoughts of self-harm or suicide.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Behavioural therapy self help intervention for anxietyThe intervention will involve five key components: Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease. Cognitions - Identify and challenge negative automatic thoughts associated with anxiety. Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH. Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure. Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving. | Other | Intervention arm |
Primary outcome
Change in Generalised Anxiety Disorder-7 (GAD-7)
Time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up
The Generalised Anxiety Disorder-7 (GAD-7) is a seven-item scale, self-administered screening tool and anxiety severity measure for anxiety disorders including, generalised anxiety disorder, social anxiety and panic disorder. Scores range from 0-21. A score of 0-4 indicates "no difficulties", 5-9 "mild", 10-14 "moderate" and 15-21 "severe" levels. A higher score suggests greater anxiety.
5 secondary outcomes
Change in Patient Health Questionnaire-9 (PHQ9)
Time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in emPHasis-10
Time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in Dyspnoea 12 (D12)
Time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in Mastery Scale
Time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up
Change in Cognitive Behavioural Processes Questionnaire (CBPQ)
Time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2020.
- Background: PubMed 16717171Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
- Background: PubMed 24232702Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, Pollock V, Armstrong I. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014 Apr;43(4):1106-13. doi: 10.1183/09031936.00127113. Epub 2013 Nov 14.
- Background: PubMed 19996336Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010 Jan;65(1):21-6. doi: 10.1136/thx.2009.118521. Epub 2009 Dec 8.
- Individual participant dataSharing planned: No. Participant's data will not be shared with researchers outside of the research team. Participants will be anonymised in all publications.
Related trials for Pulmonary Hypertension
RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Pulmonary Arterial Hypertension
Active, not recruitingPhase 2
Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH
Pulmonary Hypertension of Newborn, Diaphragm Defect
Active, not recruitingObservational study
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Pulmonary Hypertension, Interstitial Lung Disease
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
RecruitingPhase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gregg H Rawlings, PhD principal investigator
University of Sheffield
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Behavioural therapy self help intervention for anxiety in people with Pulmonary Hypertension and Pulmonary Arterial Hypertension, run by University of Sheffield at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Gregg H Rawlings, PhD ((+44) (0)114 2226610, ghrawlings1@sheffield.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Generalised Anxiety Disorder-7 (GAD-7) (time frame: pre intervention, post intervention (4 weeks after) and 1 month follow up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04450862, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2020.